Evidence map›Paper›PMID 39741187›Full record

ArticleExperimental & molecular medicine2025

Loss of YTHDC1 m

Jinyun Xu, Jonas Koch, Claudia Schmidt, Malin Nientiedt, Manuel Neuberger, Philipp Erben, Maurice Stephan Michel, Manuel Rodríguez-Paredes, Frank Lyko

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. TRMT6/TRMT61A-mediated tRNA mCellular & molecular biology letters · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinyun XuDivision of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, 69120, Heidelberg, Germany.
Jonas KochDivision of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, 69120, Heidelberg, Germany.
Claudia SchmidtCore Facility Unit Light Microscopy, German Cancer Research Center, 69120, Heidelberg, Germany.
Malin NientiedtDepartment of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, 68167, Mannheim, Germany.
Manuel NeubergerDepartment of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, 68167, Mannheim, Germany.
Philipp ErbenDepartment of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, 68167, Mannheim, Germany.
Maurice Stephan MichelDepartment of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, 68167, Mannheim, Germany.
Manuel Rodríguez-ParedesDivision of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, 69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5471-4277
Frank LykoDivision of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, 69120, Heidelberg, Germany. f.lyko@dkfz.de.

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 439669440 TRR319 RMaP TP A01Deutsche Gesellschaft für Urologie (German Society of Urology) NeM1/FE-20
6 · The paper itself

Abstract

Bladder cancer poses significant clinical challenges due to its high metastatic potential and poor prognosis, especially when it progresses to muscle-invasive stages. Here, we show that the m

Indexed as

Urinary Bladder NeoplasmsCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessUrothelium

Identifiers

PMID39741187
PMCPMC11799412

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.